![Thomas Mackie](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Thomas Mackie
Oprichter bij TomoTherapy, Inc.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
John Neis | M | 68 |
Cellectar, Inc.
![]() Cellectar, Inc. Miscellaneous Commercial ServicesCommercial Services Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way.
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI.
TomoTherapy, Inc.
![]() TomoTherapy, Inc. Medical SpecialtiesHealth Technology TomoTherapy, Inc. manufactures and provides radiation treatment systems for advanced radiation therapy. It provides radiation treatment services for cancer patients with its TomoTherapy Hi·Art System, which changes the intensity of the radiation beam so that it adapts to the shape of the tumor. The firm's system focuses on killing cancer cells while sparing healthy tissue. The company was founded by Thomas Rockwell Mackie and Paul J. Reckwerdt in 1997 and is headquartered in Madison, WI.
The Morgridge Institute for Research, Inc.
![]() The Morgridge Institute for Research, Inc. Miscellaneous Commercial ServicesCommercial Services The Morgridge Institute for Research, Inc. is a biosciences research institution. The private company is based in Madison, WI. The CEO of the company is Brad Schwartz. | 16 jaar |
Gregory R. Piefer | M | - |
Illuminated Holdings, Inc.
![]() Illuminated Holdings, Inc. Financial ConglomeratesFinance Illuminated Holdings, Inc. operates as an investment holding company. The company is headquartered in Janesville, WI.
SHINE Technologies LLC
![]() SHINE Technologies LLC Pharmaceuticals: MajorHealth Technology SHINE Technologies LLC manufactures radioisotopes for nuclear medicine. Its products include Molybdenum-99, Iodine-131, Iodine-125, and Xenon-133. The company was founded by Gregory R. Piefer and is headquartered in Monona, WI. | 14 jaar |
Adam Uselmann | M | - |
OnLume, Inc.
![]() OnLume, Inc. Medical SpecialtiesHealth Technology OnLume, Inc. operates as a medical device company. It provides ergonomic solutions for precise fluorescence image-guided surgery. The company was founded by Adam Uselmann, Benjamin Titz, Andreas Velten, Kevin Eliceiri and Thomas Rockwell Mackie and is headquartered in Madison, WI. | - |
Peter Muir | M | - |
Centaur Health Holdings, Inc.
![]() Centaur Health Holdings, Inc. Medical SpecialtiesHealth Technology Asto CT, Inc. engages in the development of x-ray computed tomography for imaging to prevent equine fractures for horses. It offers Equina, a multi-slice helical CT that allows simultaneous imaging of two limbs of a standing, sedated equine patient. The company was founded by Thomas Rockwell Mackie, Peter Muir, David L. Ergun, and Mark D. Markel in 2015 and is headquartered in Madison, WI. | 9 jaar |
Fred Robertson | M | 68 |
TomoTherapy, Inc.
![]() TomoTherapy, Inc. Medical SpecialtiesHealth Technology TomoTherapy, Inc. manufactures and provides radiation treatment systems for advanced radiation therapy. It provides radiation treatment services for cancer patients with its TomoTherapy Hi·Art System, which changes the intensity of the radiation beam so that it adapts to the shape of the tumor. The firm's system focuses on killing cancer cells while sparing healthy tissue. The company was founded by Thomas Rockwell Mackie and Paul J. Reckwerdt in 1997 and is headquartered in Madison, WI.
The Morgridge Institute for Research, Inc.
![]() The Morgridge Institute for Research, Inc. Miscellaneous Commercial ServicesCommercial Services The Morgridge Institute for Research, Inc. is a biosciences research institution. The private company is based in Madison, WI. The CEO of the company is Brad Schwartz.
SHINE Technologies LLC
![]() SHINE Technologies LLC Pharmaceuticals: MajorHealth Technology SHINE Technologies LLC manufactures radioisotopes for nuclear medicine. Its products include Molybdenum-99, Iodine-131, Iodine-125, and Xenon-133. The company was founded by Gregory R. Piefer and is headquartered in Monona, WI. | 8 jaar |
Terry Sivesind | M | - |
Cellectar, Inc.
![]() Cellectar, Inc. Miscellaneous Commercial ServicesCommercial Services Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way.
Wisconsin Investment Partners LLC
![]() Wisconsin Investment Partners LLC Investment ManagersFinance Wisconsin Investment Partners LLC (Wisconsin Investment Partners) is a venture capital firm founded in 2000 by Dick Leazer and Terry Sivesind. The firm is headquartered in Madison, Wisconsin. | - |
David L. Ergun | M | - |
Centaur Health Holdings, Inc.
![]() Centaur Health Holdings, Inc. Medical SpecialtiesHealth Technology Asto CT, Inc. engages in the development of x-ray computed tomography for imaging to prevent equine fractures for horses. It offers Equina, a multi-slice helical CT that allows simultaneous imaging of two limbs of a standing, sedated equine patient. The company was founded by Thomas Rockwell Mackie, Peter Muir, David L. Ergun, and Mark D. Markel in 2015 and is headquartered in Madison, WI. | 9 jaar |
Carl E. Gulbrandsen | M | - |
OnLume, Inc.
![]() OnLume, Inc. Medical SpecialtiesHealth Technology OnLume, Inc. operates as a medical device company. It provides ergonomic solutions for precise fluorescence image-guided surgery. The company was founded by Adam Uselmann, Benjamin Titz, Andreas Velten, Kevin Eliceiri and Thomas Rockwell Mackie and is headquartered in Madison, WI.
University of Wisconsin
| - |
Stephen Towe | M | - |
DC Leo Cancer Care Ltd.
![]() DC Leo Cancer Care Ltd. Medical SpecialtiesHealth Technology Part of Asto CT, Inc., DC Leo Cancer Care Ltd. is a British company that aims to improve the quality of Radiation Therapy delivery and access to Radiation Therapy through the removal of gantries. The company is based in Smallfield, UK. The company's approach is built on research from across the globe showing the benefits of upright patient positioning, combined with a shift from machine rotation to patient rotation. Leo Cancer Care offers upright Proton Therapy, Radiology, and Photon Therapy solutions that provide key features and benefits to patients. The company's mission is to find a better way, a more human way to treat cancer. Leo Cancer Care was founded in 2018 by Thomas Rockwell Mackie. The CEO is Stephen Kevin Towe.
Leo Cancer Care Ltd
![]() Leo Cancer Care Ltd Medical SpecialtiesHealth Technology Part of Asto CT, Inc., Leo Cancer Care Ltd is a British company that provides upright proton therapy, radiology, and photon therapy solutions for cancer treatment. The company is based in Smallfield, UK. The company's approach is built on research from across the globe, showing the benefits of upright patient positioning and a shift from machine rotation to patient rotation, which is set to change the face of radiation therapy for good. Leo Cancer Care was founded in 2018 by Stephen Kevin Towe and Thomas Rockwell Mackie, with Stephen Kevin Towe serving as the CEO since then. | - |
Brad Taylor | M | - |
Wisconsin Investment Partners LLC
![]() Wisconsin Investment Partners LLC Investment ManagersFinance Wisconsin Investment Partners LLC (Wisconsin Investment Partners) is a venture capital firm founded in 2000 by Dick Leazer and Terry Sivesind. The firm is headquartered in Madison, Wisconsin. | - |
Todd Asmuth | M | - |
SHINE Technologies LLC
![]() SHINE Technologies LLC Pharmaceuticals: MajorHealth Technology SHINE Technologies LLC manufactures radioisotopes for nuclear medicine. Its products include Molybdenum-99, Iodine-131, Iodine-125, and Xenon-133. The company was founded by Gregory R. Piefer and is headquartered in Monona, WI. | 9 jaar |
Jamey P. Weichert | M | 67 |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI.
University of Wisconsin
| 4 jaar |
Gustavo Hugo Olivera | M | - |
TomoTherapy, Inc.
![]() TomoTherapy, Inc. Medical SpecialtiesHealth Technology TomoTherapy, Inc. manufactures and provides radiation treatment systems for advanced radiation therapy. It provides radiation treatment services for cancer patients with its TomoTherapy Hi·Art System, which changes the intensity of the radiation beam so that it adapts to the shape of the tumor. The firm's system focuses on killing cancer cells while sparing healthy tissue. The company was founded by Thomas Rockwell Mackie and Paul J. Reckwerdt in 1997 and is headquartered in Madison, WI.
University of Wisconsin
| 14 jaar |
Joshua H. Levine | M | 66 |
TomoTherapy, Inc.
![]() TomoTherapy, Inc. Medical SpecialtiesHealth Technology TomoTherapy, Inc. manufactures and provides radiation treatment systems for advanced radiation therapy. It provides radiation treatment services for cancer patients with its TomoTherapy Hi·Art System, which changes the intensity of the radiation beam so that it adapts to the shape of the tumor. The firm's system focuses on killing cancer cells while sparing healthy tissue. The company was founded by Thomas Rockwell Mackie and Paul J. Reckwerdt in 1997 and is headquartered in Madison, WI. | - |
Fred T. Lee | M | - |
University of Wisconsin
| - |
Mark D. Markel | M | - |
Centaur Health Holdings, Inc.
![]() Centaur Health Holdings, Inc. Medical SpecialtiesHealth Technology Asto CT, Inc. engages in the development of x-ray computed tomography for imaging to prevent equine fractures for horses. It offers Equina, a multi-slice helical CT that allows simultaneous imaging of two limbs of a standing, sedated equine patient. The company was founded by Thomas Rockwell Mackie, Peter Muir, David L. Ergun, and Mark D. Markel in 2015 and is headquartered in Madison, WI. | 9 jaar |
Steve Miltenberger | M | - |
SHINE Technologies LLC
![]() SHINE Technologies LLC Pharmaceuticals: MajorHealth Technology SHINE Technologies LLC manufactures radioisotopes for nuclear medicine. Its products include Molybdenum-99, Iodine-131, Iodine-125, and Xenon-133. The company was founded by Gregory R. Piefer and is headquartered in Monona, WI. | - |
Anton Asmuth | M | - |
Illuminated Holdings, Inc.
![]() Illuminated Holdings, Inc. Financial ConglomeratesFinance Illuminated Holdings, Inc. operates as an investment holding company. The company is headquartered in Janesville, WI. | - |
Benjamin Titz | M | - |
OnLume, Inc.
![]() OnLume, Inc. Medical SpecialtiesHealth Technology OnLume, Inc. operates as a medical device company. It provides ergonomic solutions for precise fluorescence image-guided surgery. The company was founded by Adam Uselmann, Benjamin Titz, Andreas Velten, Kevin Eliceiri and Thomas Rockwell Mackie and is headquartered in Madison, WI. | - |
Janet Wong | F | 65 |
Illuminated Holdings, Inc.
![]() Illuminated Holdings, Inc. Financial ConglomeratesFinance Illuminated Holdings, Inc. operates as an investment holding company. The company is headquartered in Janesville, WI.
SHINE Technologies LLC
![]() SHINE Technologies LLC Pharmaceuticals: MajorHealth Technology SHINE Technologies LLC manufactures radioisotopes for nuclear medicine. Its products include Molybdenum-99, Iodine-131, Iodine-125, and Xenon-133. The company was founded by Gregory R. Piefer and is headquartered in Monona, WI. | 2 jaar |
Dick Leazer | M | - |
Wisconsin Investment Partners LLC
![]() Wisconsin Investment Partners LLC Investment ManagersFinance Wisconsin Investment Partners LLC (Wisconsin Investment Partners) is a venture capital firm founded in 2000 by Dick Leazer and Terry Sivesind. The firm is headquartered in Madison, Wisconsin. | - |
Joan Edelman Spero | M | 79 |
The Morgridge Institute for Research, Inc.
![]() The Morgridge Institute for Research, Inc. Miscellaneous Commercial ServicesCommercial Services The Morgridge Institute for Research, Inc. is a biosciences research institution. The private company is based in Madison, WI. The CEO of the company is Brad Schwartz. | - |
Andreas Velten | M | - |
OnLume, Inc.
![]() OnLume, Inc. Medical SpecialtiesHealth Technology OnLume, Inc. operates as a medical device company. It provides ergonomic solutions for precise fluorescence image-guided surgery. The company was founded by Adam Uselmann, Benjamin Titz, Andreas Velten, Kevin Eliceiri and Thomas Rockwell Mackie and is headquartered in Madison, WI. | - |
Kevin Eliceiri | M | - |
OnLume, Inc.
![]() OnLume, Inc. Medical SpecialtiesHealth Technology OnLume, Inc. operates as a medical device company. It provides ergonomic solutions for precise fluorescence image-guided surgery. The company was founded by Adam Uselmann, Benjamin Titz, Andreas Velten, Kevin Eliceiri and Thomas Rockwell Mackie and is headquartered in Madison, WI. | - |
David A. Newberg | M | - |
Illuminated Holdings, Inc.
![]() Illuminated Holdings, Inc. Financial ConglomeratesFinance Illuminated Holdings, Inc. operates as an investment holding company. The company is headquartered in Janesville, WI.
SHINE Technologies LLC
![]() SHINE Technologies LLC Pharmaceuticals: MajorHealth Technology SHINE Technologies LLC manufactures radioisotopes for nuclear medicine. Its products include Molybdenum-99, Iodine-131, Iodine-125, and Xenon-133. The company was founded by Gregory R. Piefer and is headquartered in Monona, WI. | - |
Holli Ladhani | F | 53 |
Illuminated Holdings, Inc.
![]() Illuminated Holdings, Inc. Financial ConglomeratesFinance Illuminated Holdings, Inc. operates as an investment holding company. The company is headquartered in Janesville, WI.
SHINE Technologies LLC
![]() SHINE Technologies LLC Pharmaceuticals: MajorHealth Technology SHINE Technologies LLC manufactures radioisotopes for nuclear medicine. Its products include Molybdenum-99, Iodine-131, Iodine-125, and Xenon-133. The company was founded by Gregory R. Piefer and is headquartered in Monona, WI. | 2 jaar |
James A. Thomson | M | 65 |
The Morgridge Institute for Research, Inc.
![]() The Morgridge Institute for Research, Inc. Miscellaneous Commercial ServicesCommercial Services The Morgridge Institute for Research, Inc. is a biosciences research institution. The private company is based in Madison, WI. The CEO of the company is Brad Schwartz.
University of Wisconsin
| 21 jaar |
Michael S. Robb | M | 76 |
University of Wisconsin
| - |
David J. Beebe | M | - |
University of Wisconsin
| - |
David Lyle Warnock | M | 66 |
University of Wisconsin
| - |
V. Scott Solberg | M | - |
University of Wisconsin
| - |
John J. Pershing | M | - |
University of Wisconsin
| - |
Jorge Osorio | M | - |
University of Wisconsin
| - |
Jon S. Thorson | M | - |
University of Wisconsin
| - |
Warren Porter | M | - |
University of Wisconsin
| - |
Malcolm Brett | M | - |
University of Wisconsin
| - |
Paul Barford | M | - |
University of Wisconsin
| - |
JoAnne Robbins | M | - |
University of Wisconsin
| - |
Carolyn Martin | F | - |
University of Wisconsin
| - |
Susan Michaud | F | - |
University of Wisconsin
| - |
Martha Gaines | F | - |
University of Wisconsin
| - |
Colin Welch | M | 54 |
University of Wisconsin
| - |
William Reznikoff | M | - |
University of Wisconsin
| 54 jaar |
Stanley B. Stallworth | M | - |
University of Wisconsin
| - |
Marcia Carlson | M | - |
University of Wisconsin
| - |
Thomas Reps | M | - |
University of Wisconsin
| 39 jaar |
Brian Gould | M | - |
University of Wisconsin
| - |
Douglas G. McNeel | M | - |
University of Wisconsin
| - |
Jignesh Patel | M | 53 |
University of Wisconsin
| 16 jaar |
Yuri P. Danilov | M | 67 |
University of Wisconsin
| 16 jaar |
Joseph Walsh | M | - |
University of Wisconsin
| 16 jaar |
Susan Ottmann | F | 58 |
University of Wisconsin
| 9 jaar |
Thomas Thielke | M | - |
University of Wisconsin
| - |
Salvador Carranza | M | - |
University of Wisconsin
| - |
Ron Weidemann | M | - |
University of Wisconsin
| - |
Ryan Bennett | M | - |
University of Wisconsin
| - |
Hector F. DeLuca | M | - |
University of Wisconsin
| - |
Paul A. Spaude | M | - |
University of Wisconsin
| - |
James M. Rossmeissl | M | - |
University of Wisconsin
| - |
Barbara L. Bartell | F | - |
University of Wisconsin
| - |
John D. Folts | M | - |
University of Wisconsin
| - |
William F. Banholzer | M | 67 |
University of Wisconsin
| - |
José M. Delgado | M | - |
University of Wisconsin
| - |
Robert M. Goodman | M | - |
University of Wisconsin
| - |
Christopher Graham | M | - |
University of Wisconsin
| - |
Patrick A. Thiele | M | 73 |
University of Wisconsin
| - |
Martin Rosenberg | M | 78 |
University of Wisconsin
| - |
Carlos E. Santiago | M | 71 |
University of Wisconsin
| - |
Steven Pogorzelski | M | 62 |
University of Wisconsin
| - |
Mary Ellen Bowers | F | 67 |
University of Wisconsin
| - |
James R. Imhoff | M | 80 |
University of Wisconsin
| - |
Louis LeCalsey | M | 84 |
University of Wisconsin
| - |
Patti McGill Peterson | M | 81 |
University of Wisconsin
| 17 jaar |
Margaret Clagett-Dame | M | - |
University of Wisconsin
| 35 jaar |
Richard A. Huseby | M | - |
University of Wisconsin
| - |
Ann M. Murphy | F | - |
University of Wisconsin
| - |
Steven P. Iverson | M | - |
University of Wisconsin
| - |
Jeffrey P. Miller | M | - |
University of Wisconsin
| 36 jaar |
Gary Kusnierz | M | - |
University of Wisconsin
| - |
Michael Carter | M | - |
University of Wisconsin
| - |
Darrell Bazzell | M | - |
University of Wisconsin
| - |
Leslie Ann Howard | F | - |
University of Wisconsin
| - |
Robert Hamers | M | - |
University of Wisconsin
| 34 jaar |
Robert C. West | M | - |
University of Wisconsin
| - |
William L. Murphy | M | - |
University of Wisconsin
| - |
Ruth Brown | F | - |
University of Wisconsin
| - |
Katharyn A. May | M | - |
University of Wisconsin
| - |
David H. Gilbert | M | - |
University of Wisconsin
| - |
B. Lynn Allen-Hoffmann | M | - |
University of Wisconsin
| 26 jaar |
William E. Fahl | M | - |
University of Wisconsin
| - |
Paul Papke | M | - |
University of Wisconsin
| - |
Derek M.D. Chen | M | - |
University of Wisconsin
| - |
Robert Golden | M | - |
University of Wisconsin
| - |
Neil A. Duffie | M | - |
University of Wisconsin
| - |
James R. Hayes | M | - |
University of Wisconsin
| - |
Nicholas Tincher | M | - |
University of Wisconsin
| - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Harry Palmin | M | 54 |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 15 jaar |
John Patrick Genn | M | 67 |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI.
Cellectar, Inc.
![]() Cellectar, Inc. Miscellaneous Commercial ServicesCommercial Services Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way. | 3 jaar |
James Manuso | M | 75 |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 7 jaar |
Joanne M. Protano | F | 55 |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 8 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 99 | 99.00% |
Verenigd Koninkrijk | 1 | 1.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Thomas Mackie
- Persoonlijk netwerk